Who are Metoprolol succinate + doxazosin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metoprolol-succinate-doxazosin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metoprolol succinate + doxazosin — Competitive Intelligence Brief

Metoprolol succinate + doxazosin (Metoprolol succinate + doxazosin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker + Alpha-1 adrenergic antagonist combination. Area: Cardiovascular.

marketed Beta-blocker + Alpha-1 adrenergic antagonist combination Beta-1 adrenergic receptor; Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Metoprolol succinate + doxazosin (Metoprolol succinate + doxazosin) — University of Colorado, Denver. This combination reduces blood pressure by blocking beta-adrenergic receptors (metoprolol) to decrease heart rate and cardiac output, while blocking alpha-1 adrenergic receptors (doxazosin) to relax blood vessels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metoprolol succinate + doxazosin TARGET	Metoprolol succinate + doxazosin	University of Colorado, Denver	marketed	Beta-blocker + Alpha-1 adrenergic antagonist combination	Beta-1 adrenergic receptor; Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker + Alpha-1 adrenergic antagonist combination class)

University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metoprolol succinate + doxazosin — Competitive Intelligence Brief. https://druglandscape.com/ci/metoprolol-succinate-doxazosin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab